Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Clinical trial NCT02715011 · COMPLETED
Trial details
- NCT number
- NCT02715011
- Sponsor
- Janssen Research & Development, LLC
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-06-01
- Primary completion
- 2021-03-26
- Enrollment
- 62
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.